-
A prominent and seasoned company in the healthcare industry appears to be interested in acquiring the biotech firm.
-
Per a report, the discussions regarding a potential transaction are still in the initial phases.
The clinical-stage biotech Protagonist Therapeutics (NASDAQ: PTGX) saw a significant surge in its stock price on Friday, jumping by an impressive 29.8% amid rampant speculation of a takeover. This rise is especially remarkable given that the overall market was down, with the S&P 500 (SNPINDEX: ^GSPC) dropping nearly 3% that day.
The speculation was ignited by a report from The Wall Street Journal, which suggested that Johnson & Johnson, a major player in the healthcare space, is in talks to acquire Protagonist. The report cited anonymous sources but provided little detail about the negotiations.
Protagonist Therapeutics has a working relationship with Johnson & Johnson, as both collaborate on developing a treatment for immune disorders such as ulcerative colitis. Should the drug reach the market successfully, Johnson & Johnson is set to retain exclusive marketing rights.
If the report holds merit, any acquiring company would not be purchasing Protagonist at a discount. Thanks to promising clinical trial results for several of its potential treatments, Protagonist’s stock has surged over 70% year-to-date, prior to Friday’s notable increase.
As of now, neither Protagonist nor Johnson & Johnson has commented on the WSJ report, which is typical during the early stages of such discussions. It is important to note that this remains speculation, and I would recommend that investors of either firm keep a close watch on how the situation develops.
Before you consider investing in Protagonist Therapeutics, it’s worth noting:
The Motley Fool Stock Advisor analysts have highlighted what they regard as the 10 top stocks for potential investment right now, and Protagonist Therapeutics did not make the list. The selected stocks could yield significant returns in the upcoming years.
For instance, when Netflix was featured on this list on December 17, 2004… an investment of $1,000 at that time would have grown to about $663,905!* Similarly, when Nvidia was recommended on April 15, 2005… a $1,000 investment at that point would now be approximately $1,180,428!*
